To examine if the combination prefers a subtype, we analyzed the association of the EZH2 expression with the clinical feature in our AML cohort and found that there are no significant differences in the EZH2 expression observed in the AML subtypes (Table S1). Here, EZH2 is linked to acute myeloid leukemia.